Assessment of the Effects of Zegerid Powder for Oral Suspension 40 mg on 24-Hour and Nocturnal Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease and Barrett's Esophagus.
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2017
At a glance
- Drugs Omeprazole/sodium bicarbonate (Primary)
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- 02 Jun 2017 Status changed from recruiting to discontinued.
- 01 Jun 2010 New trial record